Professional Summary
Professor HAN Baohui has spent several decades in respiratory medicine clinical practice, teaching, and translational research, focusing on lung cancer multidisciplinary comprehensive care and novel biotherapy / targeted / anti-angiogenic strategies (including immune chemotherapy clinical exploration).
He is a State Council Special Allowance recipient and has led or co authored national level lung cancer guidance/consensus, e.g. the Chinese Expert Consensus on Anti angiogenic Drug Therapy for Advanced NSCLC, and has contributed to CMA/NCCN style guideline work referenced in Chinese scholarly publications.

Position & Affiliations
•Senior Consultant, Lung Cancer MDT Team, Jiahui International Cancer Center
•Emeritus Director, Dept. of Pulmonary and Critical Care Medicine, Shanghai Chest Hospital
•Professor / Doctoral Supervisor, Shanghai Jiao Tong University School of Medicine
•Consultant of Jiahui International Cancer Center
Clinical Expertise
•Complex/high risk lung cancer diagnosis and treatment
•Targeted therapy & resistance pathways, with ongoing work in EGFR Exon20ins and novel agent development
•Biotherapy/immunotherapy + anti angiogenic combinations, including clinical trial–based care pathways

Key Research & Drug Development Role
•Principal Investigator (PI) for several pivotal clinical studies supporting Furmonertinib (伏美替尼) and other domestically developed anti cancer agents; he is especially active in EGFR exon 20 insertion (Exon20ins) and broader targeted + immunotherapy combination pathways for advanced NSCLC.
•Longstanding leadership in drug clinical trial infrastructure: Director of Shanghai Chest Hospital’s Drug Clinical Trial Institution / GCP center; NMPA (formerly CFDA) review/expert panel roles in related contexts.

Professional & Society Appointments
•Member, International Association for the Study of Lung Cancer(IASLC)
•Member, American Society of Clinical Oncology(ASCO)
•Executive President / Executive Chair, Chinese Academy of Lung Cancer
•Executive Committee Member, Chinese Society of Clinical Oncology(CSCO)
•Vice Chair, CSCO NSCLC Committee
•Standing Committee Member, Chinese Medical Association (CMA) Cancer Committee
•National Medical Products Administration (NMPA)review/assessment expert